-+ 0.00%
-+ 0.00%
-+ 0.00%

HBM partner Solstice Oncology launches Phase 2 trial of porustobart in neoadjuvant MSS stage II-III colon cancer

PUBT·09/09/2026 11:15:14
Listen to the news
HBM partner Solstice Oncology launches Phase 2 trial of porustobart in neoadjuvant MSS stage II-III colon cancer
  • HBM Holdings’ partner Solstice Oncology launched with a USD 225 million Series A to advance porustobart in neoadjuvant immuno-oncology.
  • A Phase 2 colon cancer trial is set to open for enrollment in early Q4 2026; results are expected in 2H 2027.
  • Prior results have already been presented from a Phase 2 study showing clinical activity with manageable safety, supporting earlier-line development.
  • Solstice holds rights outside Greater China under a February 2026 license, positioning porustobart for global development and commercialization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN43400) on September 09, 2026, and is solely responsible for the information contained therein.